Theravance Biopharma Stock Net Income
| TBPH Stock | USD 9.61 0.36 3.61% |
Theravance Biopharma fundamentals help investors to digest information that contributes to Theravance Biopharma's financial success or failures. It also enables traders to predict the movement of Theravance Stock. The fundamental analysis module provides a way to measure Theravance Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Theravance Biopharma stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -55.2 M | -58 M | |
| Net Loss | -60.9 M | -64 M | |
| Net Income Applicable To Common Shares | 1 B | 1.1 B | |
| Net Loss | (1.00) | (1.05) | |
| Net Income Per E B T | 1.12 | 0.82 |
Theravance | Net Income |
Theravance Biopharma Company Net Income Analysis
Theravance Biopharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Theravance Biopharma Net Income | (55.19 M) |
Most of Theravance Biopharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theravance Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Theravance Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Theravance Biopharma is extremely important. It helps to project a fair market value of Theravance Stock properly, considering its historical fundamentals such as Net Income. Since Theravance Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Theravance Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Theravance Biopharma's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Theravance Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Theravance Biopharma reported net income of (55.19 Million). This is 116.17% lower than that of the Pharmaceuticals sector and 178.8% lower than that of the Health Care industry. The net income for all United States stocks is 109.67% higher than that of the company.
Theravance Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theravance Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics of similar companies.Theravance Biopharma is currently under evaluation in net income category among its peers.
Theravance Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Theravance Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Theravance Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Theravance Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Theravance Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Theravance Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Theravance Biopharma's value.| Shares | Pictet Asset Manangement Sa | 2024-06-30 | 878.7 K | Geode Capital Management, Llc | 2024-06-30 | 857.4 K | D. E. Shaw & Co Lp | 2024-06-30 | 758.1 K | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 586.6 K | Bank Of America Corp | 2024-06-30 | 476.2 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 458.4 K | Northern Trust Corp | 2024-09-30 | 383.8 K | Wellington Management Company Llp | 2024-06-30 | 350.6 K | Nuveen Asset Management, Llc | 2024-06-30 | 342.7 K | Madison Avenue Partners, Lp | 2024-06-30 | 8.5 M | Weiss Asset Management Lp | 2024-06-30 | 7.5 M |
Theravance Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0641 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.55) % | ||||
| Current Valuation | 443.89 M | ||||
| Shares Outstanding | 49.17 M | ||||
| Shares Owned By Insiders | 5.92 % | ||||
| Shares Owned By Institutions | 96.75 % | ||||
| Number Of Shares Shorted | 4.92 M | ||||
| Price To Earning | (6.20) X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 7.76 X | ||||
| Revenue | 57.42 M | ||||
| Gross Profit | (12.05 M) | ||||
| EBITDA | (40.87 M) | ||||
| Net Income | (55.19 M) | ||||
| Cash And Equivalents | 132.85 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 49.16 M | ||||
| Debt To Equity | 652.20 % | ||||
| Current Ratio | 4.74 X | ||||
| Book Value Per Share | 3.79 X | ||||
| Cash Flow From Operations | (27 M) | ||||
| Short Ratio | 31.50 X | ||||
| Earnings Per Share | (1.03) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 13.2 | ||||
| Number Of Employees | 99 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 490.27 M | ||||
| Total Asset | 382 M | ||||
| Retained Earnings | (909.1 M) | ||||
| Working Capital | 108.77 M | ||||
| Current Asset | 237.47 M | ||||
| Current Liabilities | 49.47 M | ||||
| Net Asset | 382 M |
About Theravance Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out Theravance Biopharma Piotroski F Score and Theravance Biopharma Altman Z Score analysis. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.